Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intramuscular AMG0001 Gene Therapy for Peripheral Arterial Disease
jRCTs053180162Completed
- Sponsor
- AnGes, Inc.
- Start
- Sep 2014
- Modality
- Gene Therapies, Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of beperminogene perplasmid in arteriosclerosis obliterans, sponsored by AnGes, Inc. Primary endpoint: Primary endpoint: rest pain or ulcer size improvement at 12 weeks. Started Sep 2014; status: completed.
02
Drugs
beperminogene perplasmid
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on jRCTs053180162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs053180162.